Asunto(s)

Asunto(s)

Asunto(s)

Asunto(s)

RESUMEN

INTRODUCTION: Renal dysfunction is a main limiting factor of applying and up-titrating guideline-directed medical therapy (GDMT) among patients with heart failure with reduced ejection fraction (HFrEF). OBJECTIVE: Our retrospective monocentric observational study aimed to analyse the application ratio of combined neurohormonal antagonist therapy (RASi: ACEI/ARB/ARNI + ßB + MRA) and 12-month all-cause mortality differences in terms of renal dysfunction among HFrEF patients hospitalized for heart failure. METHOD: We retrospectively analysed the cohort of consecutive HFrEF patients, hospitalized at the Heart Failure Unit of our tertiary cardiological centre in 2019-2021. The application ratio of discharge triple therapy (TT) in five groups established on admission eGFR parameters, representing severity of renal dysfunction (eGFR≥90, eGFR = 60-89, eGFR = 45-59, eGFR = 30-44, eGFR<30 ml/min/1.73 m2) was investigated with chi-square test, while 12-month mortality differences were analysed with Kaplan-Meier method and log-rank test. RESULTS: 257 patients were included. Median eGFR was 57 (39-75) ml/min/1.73 m2, 54% of patients had eGFR<60 ml/min/1.73 m2. The proportion of patients in eGFR≥90, 60-89, 45-59, 30-44, <30 ml/min/1.73 m2 subgroups was 12%, 34%, 18%, 21%, 15%, respectively. 2% of patients were on dialysis. Even though the application rate of TT was notably high (77%) in the total cohort, more severe renal dysfunction led to a significantly lower implementation rate of TT (94%, 86%, 91%, 70%, 34%; p<0.0001): the application rate of RASi (100%, 98%, 96%, 89%, 50%, p<0.0001), ßB (94%, 88%, 96%, 79%, 68%; p = 0.003) and MRA therapy (97%, 99%, 98%, 94%, 82%; p = 0.001) differed significantly. 12-month all-cause mortality was 23% in the whole cohort. Mortality rates were higher in more severe renal dysfunction (3%, 15%, 22%, 31%, 46%; p<0.0001). CONCLUSION: Even though the proportion of patients on TT in the whole cohort was remarkably high, renal dysfunction led to a significantly lower application ratio of TT, associating with worse survival. Our results highlight that despite renal dysfunction the application of HFrEF cornerstone pharmacotherapy is essential. Orv Hetil. 2023; 164(35): 1387-1396.

Asunto(s)

RESUMEN

INTRODUCTION: Development in paediatric and interventional cardiology and cardiac surgery resulted in an increase in the number and average age of adult congenital heart disease patients. Comorbidities may appear with increased age leading to new challenges in the diagnosis and treatment of this complex group of patients. OBJECTIVE: The aim of this study is to compare clinical and echocardiographic parameters in adult congenital heart disease patients under our care below the age of 40 years, between 40 and 59 years and above the age of 60 years. METHOD: Data of a total of 346 patients were analyzed; 154 patients were under 40 years of age, 133 patients were between 40 and 59 years of age, and 59 patients were 60 years old or older. All adult congenital heart disease patients who underwent an outpatient examination were included in the study. As part of the physical examination, the New York Heart Association (NYHA) clinical classification of heart failure was determined, electrocardiography, echocardiography and 6-minute walk test were performed. RESULTS: Above the age of 40, the ratio of comorbidities increased, significantly more patients were classified into NYHA functional classes III-IV and the ratio of patients having a left ventricular ejection fraction below 55% significantly increased. The prevalence of arrhythmia was similar in all age groups, but an increasing tendency could be seen with age. CONCLUSION: There is a growing number of elderly adult congenital heart disease patients with comorbidities that play an important role in the management and in the outcome of congenital heart disease. New protocols and recommendations are required in the follow-up of these patients to help determining the optimal time for reoperation, intervention or heart transplantation. Orv Hetil. 2023; 164(6): 219-226.

Asunto(s)

RESUMEN

The different types of cardiovascular diseases, including coronary heart disease, cardiac arrhythmias and heart failure are highly prevalent in the society. Cardiovascular diseases are the leading cause of mortality. Although the influenza is forced out from the mainstream of thinking nowadays because of the ongoing SARS-CoV-2 pandemic, it still has its serious epidemiological significance. The seasonal influenza epidemic often contributes to mortality mainly, but not exclusively among old, multi-morbid patients. There are a vast number of scientific publications and evidence which prove and emphasize the synergic health-destroying and mortality-increasing effect of co-existing cardiovascular disease and influenza. Moreover, the beneficial effect of vaccination against influenza infection and its major role in prevention is also well documented. The SARS-CoV-2 pandemic enforces the importance of influenza vaccination because both viruses can lead to severe or often fatal disease, especially among old and frail patients. In addition, the younger population can be far more vulnerable against the novel coronavirus in the case of a co-existing influenza infection. International guidelines recommend influenza vaccination for patients having heart disease, like for other high-risk populations. Despite the nationally reimbursed, cost-free vaccines, the influenza vaccination rate of the society is still low not just in Hungary but also internationally. The authors review the effect of influenza infection on heart diseases, and draw attention to the role of influenza vaccination in decreasing cardiovascular morbidity and mortality.

Asunto(s)

RESUMEN

Összefoglaló. A landiolol intravénásan alkalmazandó, kifejezetten cardioselectiv, gyors hatású és rövid felezési ideju béta-1-receptor-blokkoló, mely elsosorban negatív chronotrop és inotrop hatással bír, vérnyomáscsökkento hatása elhanyagolható. Foleg hemodinamikailag instabil állapotú, supraventricularis ritmuszavarban szenvedo betegek kamrafrekvenciájának csökkentésére használható. Nagy esetszámú, randomizált vizsgálatok igazolták hatékonyságát szívmutétek után jelentkezo pitvarfibrilláció megelozésében, valamint súlyos akut szívelégtelenségben és szívmutétek posztoperatív szakában jelentkezo pitvari tachyarrhythmiák kezelésében. Ezek mellett kisebb vizsgálatok alapján a használata biztonságosnak tunik akut myocardialis infarctusban, hatékony szeptikus állapotú, pitvarfibrillációban szenvedo betegek kamrafrekvencia- és ritmuskontrolljára, valamint nem cardialis mutétek esetén a pitvarfibrilláció prevenciójára és kezelésére. Sikerrel alkalmazható elektromos vihar esetén is, és jól használható angiográfiás coronaria-CT-vizsgálat elott az optimális szívfrekvencia elérésére. A gyógyszer 2016 óta Európában, 2018 óta Magyarországon is elérheto. Orv Hetil. 2022; 163(2): 53-62. Summary. Landiolol is an intravenous, selective beta-1-receptor blocking agent with rapid onset of action and ultra-short half-life that has a predominant negative chronotropic and only mild negative inotropic effect without significant reduction of blood pressure. Landiolol is indicated to control the ventricular heart rate predominantly in patients with hemodynamic instability due to supraventricular tachyarrhythmia. Large randomized controlled trials have proven the efficacy of landiolol in the prevention of atrial fibrillation and atrial tachyarrhythmias in severe acute heart failure or post-cardiac surgery. Based on lower case-number studies, the administration of landiolol has been proven to be efficient and safe in rhythm and rate control in atrial fibrillation complicating acute myocardial infarction, sepsis, and in the prevention of atrial fibrillation in non-cardiac surgery. Landiolol may be used in electrical storm, and even during coronary CT-angiography to achieve an optimal heart rate for imaging. The drug is available in Europe since 2016 and in Hungary since 2018. Orv Hetil. 2022; 163(2): 53-62.

Asunto(s)

RESUMEN

Összefoglaló. Bevezetés: Az artériás baroreflex-érzékenységi (BRS-) indexek egységnyi nyomásváltozásra adott élettani válaszokat írnak le. Az RR-intervallum gyors válaszait a cardiovagalis BRS-indexekkel, a vasomotorválaszokat az izom szimpatikus idegi aktivitás (MSNA) válaszain alapuló szimpatikus-BRS-indexekkel jellemezzük. Szívelégtelenségben kórosan csökkent értékeik kedvezotlen kimenetelt jeleznek. Betegek és módszerek: A BRS-indexek meghatározhatóságát 52, szívelégtelenségben szenvedo betegben (kor: 59 ± 10 év; EF: 37 ± 11%) és 11, kor szerint illesztett egészséges önkéntesben vizsgáltuk. EKG- és vérnyomásfelvételekbol három cardiovagalis BRS-indexet számítottunk; a növekvo, illetve csökkeno spontán szekvenciák módszerén alapuló up-BRS-t és down-BRS-t, továbbá az alacsony frekvenciatartomány-beli 'cross-spectralis ' indexet, az LF-alfát. Egy perifériás ideg (nervus peroneus) perkután punkciójával detektáltuk az MSNA szimpatikus csúcs incidenciáját (csúcs/100 szívciklus), s ezt korreláltattuk a diastolés nyomás 3 Hgmm sávokba rendezett értékeivel. Így nyertük a szimpatikus BRS jellemzoit, a BRSSY-incidencia-értékeket. Eredmények: Az up- és down-BRS-szekvenciák csak a betegek 19%-ában voltak meghatározhatók, az LF-alfa a 69%-ukban. Azok, akiknél cardiovagalis BRS nem volt meghatározható, szignifikánsan csökkent RR-intervallum-ingadozást és magasabb NT-proBNP-értékeket mutattak. A meghatározható cardiovagalis BRS-indexek nem különítették el a betegeket és a kontrollszemélyeket. A BRSSY-incidencia-érték 58%-ban állt rendelkezésre, s csakúgy, mint maga a "csúcs" incidencia, jól elkülönítette a betegeket és az önkénteseket. A hiányzó baroreflexérték a magas "csúcs" incidenciával állt összefüggésben. Következtetés: A cardiovagalis BRS-értékek csak korlátozottan alkalmasak egészséges önkéntesek és szívelégtelen betegek elkülönítésére, a meghatározhatatlan értékek súlyosabb betegségre utalnak. A BRSSY-incidencia elkülöníti az egészséges és a beteg csoportokat; a hiányzó érték a fokozott szimpatikus aktivitással áll összefüggésben. Orv Hetil. 2021; 162(3): 91-98. INTRODUCTION: Arterial baroreflex sensitivity (BRS) is characterized by the magnitude of physiological responses to arterial pressure changes. Rapid RR interval responses are quantified by cardiovagal BRS parameters, sympathetic responses could be assessed by changes in muscle sympathetic nerve activity (MSNA). Abnormal indices in heart failure are associated with poor outcome. PATIENTS AND METHODS: 52, heart failure patients (age 59 ± 10 years, EF 37 ± 11%), and 11, age-matched healthy volunteers were studied. From ECG and arterial pressure recordings up-BRS and down-BRS values were determined using the method of spontaneous sequences. The low frequency cross-spectral gain, the LF alpha was also determined. Percutaneous puncture of the peroneal nerves allowed determination of MSNA burst incidence (burst/100 cycles), which was correlated to corresponding diastolic pressure bins of 3 mmHg, yielding a sympathetic BRS, the BRSSY-incidence. RESULTS: Up- and down-BRS could be calculated in 19% of the patients, LF alpha was determined in 69%. Those with missing cardiovagal BRS values showed diminished RR interval variation, and higher levels of NT-proBNP. The measurable cardiovagal BRS indices did not separate patients and healthy volunteers. BRSSY-incidence could be determined in 58% of the patients. The sympathetic gain as well as the burst incidence differed significantly between patients and healthy volunteers. Missing BRSSY-incidence was associated with higher burst incidence. CONCLUSION: Cardiovagal BRS indices have limited value in differentiating healthy and heart failure subjects. Incalculable values among patients indicate more severe disease state. BRSSY-incidence does separate healthy and diseased population, the missing BRSSY-incidence values are related to increased sympathetic activity. Orv Hetil. 2021; 162(3): 91-98.

Asunto(s)

RESUMEN

Heart failure is a rapidly growing epidemic in developed countries. It has been well documented that heart failure is associated with abnormal neurohumoral activation. The autonomic regulation is characterized by decreased parasympathetic and elevated sympathetic activity. While the cardiovagal activity could be easily assessed by various heart rate variability parameters, markers of the sympathetic activity are not readily available. Percutaneous insertion of microelectrodes in a peripheral nerve allows recording of the muscle sympathetic vasomotor nerve activity (MSNA). MSNA shows good correlation with the cardiac sympathetic activity, and also with the levels of circulating catecholamines. Besides determination of the baseline sympathetic activity, rapid sympathetic responses to various stimuli can be also described by changes of MSNA. Elevated MSNA has been documented in several diseases, including hypertension, obesity, myocardial ischemia and renal failure. In heart failure, the elevated MSNA is well correlated to the clinical severity of the patient's conditions, and serves as a prognostic marker of mortality. In our paper, we give a short account of the history of MSNA studies, describe its physiological background and clinical relevance with special regard to heart failure. Orv Hetil. 2020; 161(29): 1190-1199.

Asunto(s)

RESUMEN

INTRODUCTION: The incidence of dilated cardiomyopathy after anthracycline chemotherapy is mainly influenced by anthracycline cumulative dose. Previous researches showed doxorubicin treatment under cumulative dose of 450 mg/m2 associated with a low incidence of heart failure. Nowadays, doxorubicin is administered with a lower dose, the development of heart failure is largely determined by other factors. AIM: Our purpose was to identify the risk factors for heart failure due to doxorubicin therapy. METHOD: With the use of the Hungarian financial healthcare databases merged with the National Cancer Registry, we performed a retrospective study. All the patients having confirmation for breast carcinoma between 2004 and 2015 were enrolled. The subjects with a preceding period characterized by any chemotherapy or diagnoses suggesting heart failure were excluded. Heart failure outcome event was defined by the assignment of I50 diagnosis code at hospital discharge or in autopsy reports. STATISTICAL ANALYSIS: We used multivariate binary logistic regression to calculate odds ratios for heart failure. Besides the baseline characteristics, oncological state and cumulative doses of the chemotherapies were also taken into account. RESULTS: Among the analysed 3288, doxorubicin-treated patients, heart failure cumulative incidence was 6.2%. Doxorubicin cumulative dose over 400 mg/m2 increased the risk. The heart failure incidence was essentially influenced by age, even over 50 years the risk rose. Diabetes mellitus and the treatments with pyrimidine-analogues, carboplatin or bevacizumab were also associated with higher risk. CONCLUSION: By the integration of national financial and clinical databases, we could identify the risk factors for doxorubicin-associated heart failure. Orv Hetil. 2020; 161(26): 1094-1102.

Asunto(s)

RESUMEN

INTRODUCTION: Heart failure is a high mortality cardiovascular disease affecting a huge patient population. Mortality rate data and their changes are important information regarding therapy effectiveness. AIM: To study the death rate of heart failure and its change in comparison with the period before 2010. METHOD: In the year 2017, data of heart failure patients were analysed: number, overall and in-hospital mortality rate, 1-6-12-month death rates. Patients reported with codes of I50 and I42 blocks of the ICD-10 (International Statistical Classification of Diseases and Related Health Problems, 10th revision) classification were collected, irrespective of whether the codes were used as principal or additional diagnoses. Only all-cause mortality data were assessed. RESULTS: The prevalence of patients treated with heart failure was 1.1%. In-hospital death rate was 3.9% of this patient population, while 1-6-12-month death rates were 5.2-12-17%. CONCLUSIONS: The prevalence of heart failure was less in 2017 than the 1.6% value for the year 2009. This can be due to the fact that this study collected patients treated or visited only this one year, while the other study in 2009 assessed patients diagnosed also in the previous 5 years but not appearing at any medical visit in 2009. Mortality rate data have also shown a remarkable improvement in comparison with the year 2009, but they still remained above the values reported for Western Europe. This improvement can be explained with the better up-titration of medications offering longer survival and the better adherence of patients. Orv Hetil. 2020; 161(24): 1012-1014.

Asunto(s)

RESUMEN

The European Union (EU) law harmonization expects from each EU country to apply the same principles and same standards of the medical evaluation of driving licenses. All EU member states have to apply common evaluations of the driving licenses - based on the EU Regulation 2016/1006 - at the latest from January of this year. Hungary launched this new regulation on the 12th of January 2018. The most important source document of the current national regulation is the expert consensus document "New Standards for Driving and Cardiovascular Diseases" published in 2013. This is the professional evaulation of the cardiovascular diseases which can influence driving, and its importance is highlighted because even the Hungarian law listed this document as a resource. In this summary, in accordance with the current law, we provide a practical guide for the day-to-day work of assessing the permission of driving licence in connection with the different kinds of cardiovascular diseases. Orv Hetil. 2019; 160(10): 370-377.

Asunto(s)

RESUMEN

INTRODUCTION: The determination of natriuretic peptide levels in patients hospitalized for suspected acute heart failure is important for the confirmation of the diagnosis and for the prognosis. Changes in natriuretic peptide levels in response to therapy have a strong prognostic value. AIM: To decide whether repeated natriuretic peptide measurements for acute heart failure show changes that could influence the diagnosis and/or the prognosis. METHOD: Prospective data collection was carried out of N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels on admission and within 12 hours in patients hospitalized for acute heart failure. Only the data of those patients were analyzed whose symptoms started within 24 hours prior to admission and were due to acute heart failure. RESULTS: The 23 patients whose data we analyzed had an average age of 77.9 ± 8.3 years. Most of them had left ventricular systolic dysfunction with an average ejection fraction of 34.1 ± 3.9%. The time between the start of symptoms and the first measurement was 6.7 ± 2.2 hours, while the time until the repeated determination was 6.5 ± 2.2 hours after the first measurement. The median value of the NT-proBNP levels in the 6 hours control showed an increase from 5064 pg/mL to 8847 pg/mL (p<0.0005), which amounts to a 75 percent increase - mean hs-troponin T showed an increase from 46 ± 25 ng/L to 78 ± 51 ng/L (p<0.002). CONCLUSIONS: A significant increase in NT-proBNP levels is to be expected in early repeated measurement after hospital admission. This fact could have diagnostic and prognostic consequences if validated in a larger patient population. Orv Hetil. 2018; 159(25): 1009-1012.

Asunto(s)

RESUMEN

Therapy refracter heart failure is presented. The admission ECG shows low voltage and pseudoinfarct Q waves highly diagnostic for the etiology of heart failure. Orv Hetil. 2018; 159(8): 327-329.

Asunto(s)

RESUMEN

INTRODUCTION: The prognostic role of B-type natriuretic peptide (BNP) level was confirmed in chronic heart failure and congenital heart diseases irrespective of the aetiology. AIM: The aim of this study was to compare NT­proBNP measured in the clinical practice and important clinical and echocardiographic parameters in patients with adult congenital heart diseases under our care. METHOD: Data of a total of 70 patients were analysed; 34 patients had corrected tetralogy of Fallot and 19 patients had corrected transposition of the great arteries. In 17 further cases, patients with other congenital vitiums have been involved in the study. In all cases, out-patient examination was performed with electrocardiography, echocardiography and NT-proBNP measurement. The New York Heart Association (NYHA) stages of the patients were determined and the patients filled in a questionnaire regarding their quality of life. RESULTS: Elevated NT-proBNP level resulted in a worse quality of life (visual analogue scale, VAS) and an increased right ventricular end diastolic diameter; the incidence of arrhythmia increased as well. Negative correlation was found between the NT-proBNP level and the VAS value (r = -0.45, p = 0.0001) and the left ventricular ejection fraction (LV-EF) (r = -0.67, p = <0.0001). ROC analysis showed that NT­proBNP≥668.1 pg/ml was the cut-off value that most accurately predicted NYHA class III-IV (sensitivity 93%, specificity 63%, area under the curve 80%, p = 0.001). Similarly, NT-proBNP≥184.7 pg/ml was found to be the cut-off value most accurately predicting LV-EF below 55% (sensitivity 66%, specificity 67%, area under the curve 77%, p = 0.02). CONCLUSIONS: NT-proBNP has a role in the evaluation of adult patients with congenital heart diseases and in determining the prognosis of these patients, and in addition to other examinations used in the follow-up of these patients, NT-proBNP may help in determining the time of reoperation or potential heart transplantation. Orv Hetil. 2018; 159(4): 141-148.

Asunto(s)

RESUMEN

INTRODUCTION: Several studies have demonstrated that the prevalence of heart disease can be accounted for between 0.4 and 2% in developed countries. AIM: The present study aimed to use the PA% of the telemetry data to estimate the 6-minute walk test result. METHOD: A total of seventeen patients with heart disease; 3 females and 14 males; age: 57.35 yrs ± 9.54; body mass 98.71 ± 9.89 kg; average BMI 36.69 ± 3.67 were recruited into the study. Using the two sets of values describing physical performance, linear regression was calculated providing a mathematical equation, thus, the Physical Activity % value is used to estimate the distance traveled over a 6-minute walk test. RESULTS: On further data analysis, we have come to the conclusion that the distance walked during the six-minute-long test may be measured by PA% from the data of CRT device. CONCLUSIONS: With our method, based on the values received from the physical activity sensor implanted into the resynchronisation devices, changes in patients' health status could be monitored telemetrically with the assistance from the implanted electronic device. Orv Hetil. 2017; 158(35): 1390-1395.

Asunto(s)

RESUMEN

INTRODUCTION: The effect of regular physical activity on health is widely recognized, but several studies have shown its key importance for heart patients. AIM: The present study aimed to define the PA % values, and to convert them into metabolic equivalent values (MET), which describes oxygen consumption during physical activity. METHOD: A total of seventeen patients with heart disease; 3 females and 14 males; age: 57.35 yrs ± 9.54; body mass 98.71 ± 9.89 kg; average BMI 36.69 ± 3.67 were recruited into the study. The measured values from Cardiac Resynchronisation Therapy devices and outer accelerometers (ActiGraph GT3X+) were studied over a 7-day time period. Using the two sets of values describing physical performance, linear regression was calculated providing a mathematical equation, thus, the Physical Activity values in percentage were converted into MET values. RESULTS: During the 6-minute walk test the patients achieved an average of 416.6 ± 48.2 m. During 6MWT the measured values averaged at 1.85 ± 0.18 MET's, and MET values averaged at 1.12 ± 0.06 per week. It clearly shows that this test is a challenge for the patients compared to their daily regular physical activity levels. CONCLUSION: With our method, based on the values received from the physical activity sensor implanted into the resynchronisation devices, changes in patients' health status could be monitored telemetrically with the assistance from the implanted electronic device. Orv Hetil. 2017; 158(17): 748-753.

Asunto(s)

RESUMEN

INTRODUCTION: Patients hospitalized for heart failure have a very high in-hospital as well as one-year mortality. Natriuretic peptides play both a diagnostic and a prognostic role in this disease. Changes of natriuretic peptide levels in response to therapy are a well-known prognostic marker. Regarding in-hospital mortality, however, little is known about the prognostic value of extremely high levels of natriuretic peptides measured on admission. AIM: To decide whether extremely high levels of B-type natriuretic peptide have a prognostic value with regard to in-hospital mortality. METHOD: NT-proBNP levels on admission and in-hospital mortality were extracted retrospectively from the data of patients treated with heart failure in the cardiology department of the Hospital of St. John of God in Budapest. We separately analyzed the data of patients hospitalized for heart failure in 2015 with extremely high initial NT-proBNP levels. The cut-off value in this regard was 10 000 ng/l. We also analyzed the comorbidities of these patients. RESULTS: The median NT-proBNP level of those patients who survived beyond the index hospital stay in the last 10 years was 4842 ng/l, whereas the median NT-proBNP level of those 182 patients who died during their hospital stay was 10 688 ng/l (p<0.001). In the year 2015, we treated 118 patients with an NT-proBNP level above 10 000 ng/l. Thirteen of these patients died, which means that their in-hospital mortality exceeded 10%. In comparison, the in-hospital mortality of all heart failure patients was 5.8%. The difference of median NT-proBNP levels of surviving versus deceased patients in this group with extremely high NT-proBNP levels was no longer significant (17 080 ng/l vs. 19 152 ng/l). CONCLUSIONS: Patients with an NT-proBNP level of >10 000 ng/l on admission have a significantly higher in-hospital mortality. The difference of NT-proBNP levels of surviving versus deceased patients in the group with admission NT-proBNP levels >10 000 ng/l is no longer significant. We could not identify any etiological factors that would explain these extremely high NT-proBNP levels or the excess in-hospital mortality. Orv Hetil. 2017; 158(20): 779-782.

Asunto(s)

RESUMEN

The association of diabetes and heart failure is very common, furthermore, the pathophysiology and clinical course of the two entities have many crossing-points. Today, the spectrum of available anti-diabetic drugs is extremely wide, ranging from the classical (insulin, biguanides, sulphonylureas) to the most recent agents (gliptins, gliflozins). The cardiovascular effects of these drugs are multiple, their knowledge is important in the everyday practice, as the use of safe drugs regarding of heart failure is preferred. Our work provides an overview of each class of drugs after the presentation of the mechanism of action and the main representatives, the effects on the cardiovascular system, including those on heart failure will be described, mentioning the results of the most important clinical trials. The available data confirm the beneficial effects of metformin and gliflozins and the harmful effect of thiazolidinediones in heart failure. The other classes of drugs are permitted in heart failure, but it is important to continuously monitor the signs of decompensation. Orv. Hetil., 2017. 158(5), 163-171.

Asunto(s)